- $31.89bn
- $33.90bn
- $9.89bn
Deals of the day-Mergers and acquisitions
Street View: Biogen's $5.6 billion Apellis bet a strategic fit
Deals of the day-Mergers and acquisitions
U.S. RESEARCH ROUNDUP- Asana, PPG Industries, Verisign
Press Digest: Wall Street Journal - April 1
Deals of the day-Mergers and acquisitions
Biogen to buy Apellis Pharmaceuticals for $5.6 billion to expand its rare disease portfolio (updated)
Biogen to buy Apellis Pharmaceuticals for $5.6 billion
Brief: Biogen To Buy Apellis For $5.6 Billion To Boost Kidney Franchise - Bloomberg News
U.S. STOCKS ON THE MOVE-Sysco, Crowdstrike, GM
U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar
Brief: Biogen To Introduce 28 Mg Vial At Same Price As 12 Mg Vial
U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike
Royalty Pharma and J&J partner to develop autoimmune treatment
Biogen rises as FDA clears higher-dose Spinraza for muscle disease
Brief: FDA Approves New High Dose Regimen Of Spinraza® (Nusinersen) For Spinal Muscular Atrophy
US FDA approves higher-dose of Biogen's genetic disorder drug (updated)
US FDA approves higher-dose of Biogen's genetic disorder drug
Analysis: TrumpRx lists many medicines at prices higher than paid in UK